TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28423305

Group type: EXPERIMENTAL
Intervention: Evidence-based screening schedule for retinopathy based on current state of retinopathy and glycated hemoglobin levels.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Routine annual examinations for retinopathy.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Patients with no retinopathy and glycated hemoglobin level of 6%.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Patients with mild retinopathy and glycated hemoglobin level of 10%.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Patients with moderate retinopathy.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Patients with severe nonproliferative diabetic retinopathy.
Number of subjects: 1000
Study: 24256085

Group type: EXPERIMENTAL
Intervention: Bridges stroke self-management program (one session of up to one hour per week for six weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual rehabilitation only
Number of subjects: 25
Study: 25031133

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.2-1 mg/kg/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5-1.2 mg/kg/d)
Number of subjects: 69
Study: 20934481

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 10mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 40mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19243708

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Non-TZD (comparator)
Number of subjects: 1818
Study: 17316102

Group type: COMPARATOR
Intervention: Standard training (reading directions for use and trying on their own)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intensive training (individual coaching and inspiratory flow rate training)
Number of subjects: 102
Study: 15446320

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 60

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 60
Study: 11135384

Group type: EXPERIMENTAL
Intervention: Antidromic transcutaneous sacral neurostimulation during the second fill (n = 74)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group underwent a second fill without neurostimulation (n = 72)
Number of subjects: 146
Study: 9874288

Group type: EXPERIMENTAL
Intervention: Novel PCR assay combined with immunological and colorimetric detection of bcr-rearrangement
Number of subjects: 7

Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 7
Study: 8665709

Group type: EXPERIMENTAL
Intervention: Snoring group (n=17)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (cadaveric specimens, n=14)
Number of subjects: 31
Study: 2393014

Group type: EXPERIMENTAL
Intervention: 400 mL regular coffee
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 165 mL regular coffee
Number of subjects: 6

Group type: COMPARATOR
Intervention: 165 mL decaffeinated coffee
Number of subjects: 6

Group type: COMPARATOR
Intervention: 165 mL sodium chloride solution
Number of subjects: 6
Study: 343630

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.375% bupivacaine
Number of subjects: 93
Study: 30373802

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 800 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 4000 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 1500 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 3000 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Number of subjects: 97
Study: 28025216

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 26311500

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (among conscious patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning (among unconscious patients)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 144
Study: 23696054

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus steroids (ST)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tacrolimus plus mycophenolate mofetil (MMF)
Number of subjects: 75
Study: 21310910

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg/0.05 mL, given as three initial treatments with further retreatment as needed)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 131
Study: 19854514

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 118
Study: 17142654

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g iv every six hours plus oral placebo (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg po every six hours plus iv placebo (group I)
Number of subjects: 45
Study: 14617059

Group type: EXPERIMENTAL
Intervention: Iontophoresis with dexamethazone (3 ml)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Iontophoresis with saline solution (3 ml)
Number of subjects: 25
Study: 10385137

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 15538

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 15538

Group type: EXPERIMENTAL
Intervention: Both alpha-tocopherol and beta-carotene
Number of subjects: 15538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15538
Study: 8889344

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment identification by investigators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment identification by coordinators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall treatment identification
Number of subjects: 0
Study: 1889771

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy with hydroxyethyl-starch (HAES-steril) combined with pentoxifylline (Trental) for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 42
Study: 6417717

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 36
Study: 3963860

Group type: EXPERIMENTAL
Intervention: MY-1 treatment (3 times a week from the 4th postoperative day for 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study: 29198295

Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dim red light
Number of subjects: 44
Study: 27324515

Group type: EXPERIMENTAL
Intervention: 2% Chamaemelum nobile gel (0.5 mL/3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24338736

Group type: EXPERIMENTAL
Intervention: Repaglinide (3 mg/day for 8 weeks)
Number of subjects: 300
Study: 23470897

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Contact/Measurement Control
Number of subjects: 28
Study: 19657792

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (50 microg estradiol plus 170 microg norethisterone/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 50
Study: 18441460

Group type: EXPERIMENTAL
Intervention: 11C‐acetate PET
Number of subjects: 78

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 78
Study: 16332385

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg, two oral doses)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 12556688

Group type: EXPERIMENTAL
Intervention: IL-2 therapy (5 x 10(6) IU twice daily for 5 days: every 4 weeks for three cycles, then every 8 weeks for seven cycles)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (lamivudine/stavudine/indinavir)
Number of subjects: 68
Study: 10641582

Group type: EXPERIMENTAL
Intervention: 25 g oral glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 g oral glucose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8545223

Group type: EXPERIMENTAL
Intervention: High-dose surfactant therapy (beractant, 150 mg (6 mL)/kg, up to four doses, instilled every 6 hours for 20 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air placebo (6 mL/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose surfactant therapy
Number of subjects: 40
Study: 1869100

Group type: EXPERIMENTAL
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cisplatin, cyclophosphamide, and doxorubicin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical evidence of disease
Number of subjects: 32
Study: 6347788

Group type: EXPERIMENTAL
Intervention: verapamil 240 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: verapamil 360 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30633135

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2831

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2831
Study: 29336385

Group type: EXPERIMENTAL
Intervention: Betamethasone (4 mg) with/without droperidol (0.625 mg)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Betamethasone with/without droperidol (in patients with ≥2 risk factors)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Standard care (control group with ≥2 risk factors)
Number of subjects: 502
Study: 27592122

Group type: EXPERIMENTAL
Intervention: ezParent program
Number of subjects: 312
Study: 25375367

Group type: EXPERIMENTAL
Intervention: Long-acting injectable paliperidone palmitate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antipsychotic medications
Number of subjects: 0
Study: 22335830

Group type: EXPERIMENTAL
Intervention: Medial and lateral entry pinning
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lateral entry pinning
Number of subjects: 160
Study: 20646185

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1,000mg every 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLB) gel (3-6 g/daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 50
Study: 17546307

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid, cytological screening, and testing for human papillomavirus
Number of subjects: 100800

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100800
Study: 15705734

Group type: EXPERIMENTAL
Intervention: Isometric contractions (Iso)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentric contractions (Con)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eccentric contractions (Ecc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentric contractions (Con) relative to maximal Iso torque
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eccentric contractions (Ecc) relative to maximal Iso torque
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voluntary activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coactivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical responses to single and paired stimuli
Number of subjects: 0
Study: 12010906

Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: All causes
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Cardiac causes
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Angina at 5 years
Number of subjects: 3608
Study: 10582755

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 185
Study: 8826572

Group type: EXPERIMENTAL
Intervention: Valproic acid (divalproex sodium), starting dosage 250 mg bid, titrating to 1000 mg/d if necessary
Number of subjects: 0
Study: 1676225

Group type: EXPERIMENTAL
Intervention: 20G disposable needles
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 26G disposable needles
Number of subjects: 92
Study: 6373302

Group type: EXPERIMENTAL
Intervention: 5 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30993651

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 29343232

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg∙kg‐1 (Group D2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg∙kg‐1 (Group D1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intravenous saline (Group D0)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg∙kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg∙kg‐1
Number of subjects: 75
Study: 26547514

Group type: EXPERIMENTAL
Intervention: ACB + ABS
Number of subjects: 15

Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 15
Study: 24823873

Group type: EXPERIMENTAL
Intervention: Exenatide treatment group (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intensive insulin therapy group (n=30)
Number of subjects: 60
Study: 22418004

Group type: EXPERIMENTAL
Intervention: Anterior 90° partial fundoplication
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Anterior 180° partial fundoplication
Number of subjects: 461

Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 461
Study: 20403176

Group type: EXPERIMENTAL
Intervention: ECMO with cooling at 34 degrees C for 48 to 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECMO at 37 degrees C (control group)
Number of subjects: 0
Study: 18525081

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing
Number of subjects: 818

Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Computerized interview
Number of subjects: 818
Study: 15798702

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of enalapril with bisoprolol
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of enalapril with carvedilol
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of enalapril with irbesartan
Number of subjects: 84
Study: 12065984

Group type: EXPERIMENTAL
Intervention: Posterior long fusion (surgical treatment)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonoperated group (conservative treatment)
Number of subjects: 17
Study: 10452757

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8535033

Group type: EXPERIMENTAL
Intervention: goralatide (12.5 or 62.5 micrograms/kg/day, d1‐d4)
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study: 2136866

Group type: EXPERIMENTAL
Intervention: Family intervention combined with drug treatment during hospitalization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unipolar patients and families)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 0
Study: 729629

Group type: EXPERIMENTAL
Intervention: Furosemide 50 mg administered orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 50 mg administered intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide treatment
Number of subjects: 12
Study: 29669064

Group type: EXPERIMENTAL
Intervention: Text-only warning
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Graphic health warning + text
Number of subjects: 1011

Group type: COMPARATOR
Intervention: No claim (control) condition
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Control condition (no warning)
Number of subjects: 1011
Study: 28187051

Group type: EXPERIMENTAL
Intervention: High levels of PEEP (12 cmH2O)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Low levels of PEEP (≤2 cmH2O)
Number of subjects: 242
Study: 26275354

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17OHP-C)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 23706627

Group type: EXPERIMENTAL
Intervention: Minocycline 100mg orally, twice daily for 8 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21808963

Group type: EXPERIMENTAL
Intervention: Group MKH (midazolam 0.5 mg/kg and ketamine 6 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group MKL (midazolam 0.25 mg/kg and ketamine 3 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group M (midazolam 0.5 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group MKL
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group M
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group MKH
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group MKL and Group MKH
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Group M, Group MKL, Group MKH
Number of subjects: 87
Study: 19456855

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Both doses of amitriptyline
Number of subjects: 132
Study: 16770567

Group type: EXPERIMENTAL
Intervention: IM warm-up (IMW) with 40% maximum inspiratory mouth pressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo IM warm-up (IMW(P)) with 15% maximum inspiratory mouth pressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control trial without IM warm-up
Number of subjects: 10
Study: 15326251

Group type: EXPERIMENTAL
Intervention: High-dose betaINF-1a (60 microg IM/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11241549

Group type: EXPERIMENTAL
Intervention: 50 mg bicalutamide (Casodex)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9250639

Group type: EXPERIMENTAL
Intervention: EMLA (0.15 g/kg, maximum 5.0 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TAC (0.1 mL/kg, maximum 3.0 mL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 32

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EMLA and TAC
Number of subjects: 32
Study: 7924888

Group type: EXPERIMENTAL
Intervention: Power spectral analysis (PSA) of heart rate variations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibratory perception threshold (VPT) measured with a Suzuki‐Matsuoka Vibrometer (SMV‐5)
Number of subjects: 0
Study: 2900918

Group type: EXPERIMENTAL
Intervention: 2 mg ethyl loflazepate (CM 6912)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 mg ethyl loflazepate (CM 6912)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 12
Study: 31945496

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiol antioxidants (NAC/GSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) with malabaricone C (mal C)
Number of subjects: 0
Study: 30949691

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention with a Registered Dietitian Nutritionist, including a minimum of 6 one-on-one counseling sessions over ∼30 weeks focusing on healthy diet and physical activity goals.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care (UC), n=24.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention with a Registered Dietitian Nutritionist.
Number of subjects: 47
Study: 28282363

Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS) scores
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Baseline MCS scores
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Baseline pain visual analog scale
Number of subjects: 520
Study: 27467702

Group type: EXPERIMENTAL
Intervention: Detached mindfulness
Number of subjects: 8

Group type: COMPARATOR
Intervention: Brief exposure to alcohol-related thoughts
Number of subjects: 8
Study: 23406728

Group type: EXPERIMENTAL
Intervention: PEP02 120 mg/m²
Number of subjects: 44

Group type: COMPARATOR
Intervention: irinotecan 300 mg/m²
Number of subjects: 44

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m²
Number of subjects: 44
Study: 21215709

Group type: EXPERIMENTAL
Intervention: Laparoscopic simulator (Teenaged video gamers)
Number of subjects: 30
Study: 19925613

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (600 kcal/d)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control supplement (200 kcal/d)
Number of subjects: 253
Study: 16914336

Group type: EXPERIMENTAL
Intervention: FSC 500/50 microg Diskus, 1 inhalation twice daily + placebo Handihaler, 1 inhalation once daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg Handihaler, 1 inhalation once daily + placebo Diskus, 1 inhalation twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FSC 500/50 microg Diskus, 1 inhalation twice daily + tiotropium 18 microg Handihaler, 1 inhalation once daily
Number of subjects: 90
Study: 14982910

Group type: EXPERIMENTAL
Intervention: Reteplase plus abciximab
Number of subjects: 253

Group type: COMPARATOR
Intervention: Abciximab alone
Number of subjects: 253